No Data
No Data
Global Non-invasive Aesthetic Treatment Market Analysis Report 2024-2032 Featuring Johnson & Johnson, Bausch, Cutera, AbbVie, Sisram Medical, Galderma, Sientra, and Revance Therapeutics
Revance to Participate in Upcoming Investor Conferences
Revance Therapeutics Price Target Cut to $11.00/Share From $12.00 by HC Wainwright & Co.
Revance Therapeutics Is Maintained at Neutral by Goldman Sachs
Express News | Goldman Sachs Maintains Neutral on Revance Therapeutics, Lowers Price Target to $8
Barclays Sticks to Its Buy Rating for Revance Therapeutics (RVNC)
No Data